Comparison of Population Pharmacokinetics‐Related Information in Drug Labeling Between Japan, the United States, and the European Union

Ähnliche Einträge

• Background Factors Contributing to Safety Warning Discordance in the Initial Labeling of New Drugs in Japan, the United States, and the European Union
  von: Koichi Fukuda, et al.
  Veröffentlicht: (2024)
• Drug Loss in Japan: A Comparative Analysis with Europe for New Drugs Developed by Emerging Biopharma Companies
  von: Mihoko Kobayashi, et al.
  Veröffentlicht: (2025)
• Statin Drug‐Drug Interactions: Pharmacokinetic Basis of FDA Labeling Recommendations and Comparison Across Common Tertiary Clinical Resources
  von: James Mease, et al.
  Veröffentlicht: (2024)
• Physiologically Based Pharmacokinetic Modeling of Vancomycin and its Comparison with Population Pharmacokinetic Model in Neonates
  von: Ailing Cao, et al.
  Veröffentlicht: (2024)
• An Investigation in the Comparability of the Exposure and Recommended Dose of Selected Pfizer Drugs in East Asian Countries: Is Mutual Usage of Clinical Data Among East Asian Countries Feasible?
  von: Diane D. Wang, et al.
  Veröffentlicht: (2024)